Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Location
8000 Marina Boulevard, Suite 120, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.45K % +106%
Debt-to-equity 28.8 % -25.9%
Return On Equity -47.6 % +46.7%
Return On Assets -36.9 % +42.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.8M shares +23.7%
Entity Public Float 449M USD +175%
Common Stock, Value, Issued 55K USD
Weighted Average Number of Shares Outstanding, Basic 54.7M shares +23.6%
Weighted Average Number of Shares Outstanding, Diluted 54.7M shares +23.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 89.4M USD +1.97%
General and Administrative Expense 27.8M USD +14.2%
Operating Income (Loss) -117M USD -4.63%
Nonoperating Income (Expense) 9.39M USD +99.6%
Income Tax Expense (Benefit) 1K USD
Net Income (Loss) Attributable to Parent -108M USD -0.47%
Earnings Per Share, Basic -2.17 USD/shares +35.2%
Earnings Per Share, Diluted -2.17 USD/shares +35.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.1M USD -26%
Marketable Securities, Current 359M USD +144%
Other Assets, Current 429K USD -69.3%
Assets, Current 395M USD +107%
Property, Plant and Equipment, Net 155K USD +288%
Operating Lease, Right-of-Use Asset 1.93M USD -52.1%
Assets 397M USD +104%
Accounts Payable, Current 4.66M USD -64.9%
Employee-related Liabilities, Current 2.58M USD +28.9%
Accrued Liabilities, Current 11.6M USD +5.85%
Liabilities, Current 18.4M USD -31.4%
Operating Lease, Liability, Noncurrent 455K USD -82.3%
Liabilities 69.4M USD +27%
Accumulated Other Comprehensive Income (Loss), Net of Tax -450K USD -217%
Retained Earnings (Accumulated Deficit) -371M USD -41%
Stockholders' Equity Attributable to Parent 328M USD +133%
Liabilities and Equity 397M USD +104%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.8M USD -28.7%
Net Cash Provided by (Used in) Financing Activities 277M USD +156%
Net Cash Provided by (Used in) Investing Activities -219M USD -1892%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.4M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 69.1M USD -49.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.52M USD -53.3%
Deferred Tax Assets, Valuation Allowance 71.4M USD +43.8%
Deferred Tax Assets, Gross 72.1M USD +42.1%
Operating Lease, Liability 2.57M USD -49.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 3.37M USD -47.4%
Operating Lease, Liability, Current 2.12M USD -17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.88M USD -37.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 802K USD -37.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 27.5M USD +25.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.51M USD +60.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 764K USD +2.41%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 719K USD -33.8%
Share-based Payment Arrangement, Expense 15.1M USD +43.5%
Interest Expense 5.82M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%